VITROPHAGE'S PMA FOR VITREON RETINAL TAMPONADE IS APPROVABLE DESPITE HEAVY CRITICISM FROM PANEL; INFINITECH'S PERFLUORON PMA CLEARS PANEL WITH PRAISE
This article was originally published in The Gray Sheet
Executive Summary
Two intraoperative retinal tamponades -- Vitrophage's Vitreon and Infinitech's Perfluoron -- were deemed approvable by FDA's Ophthalmic Devices Panel at an Oct. 19 session in Gaithersburg, Maryland. Both firms are seeking approval of the liquid perfluorocarbon devices as intraoperative surgical aids to assist in reattaching the retina in patients with certain complex retinal complications.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.